JOHNSON & JOHNSON Q3 FY2026 earnings call

• Overall Performance: J&J reported operational sales growth of 6% in Q3, exceeding consensus. The company is on track to exceed $100 billion in annual revenue for the first time in its history.
• Innovative Medicine Strength: The division delivered 7.9% operational growth, fueled by double-digit gains in eight brands. Oncology is a primary engine, with management aiming to become the #1 oncology company by 2030 ($50B+ sales target).
• New Product Momentum: Icotide (psoriasis) launched strongly with >20,000 patients treated. Inlexo (bladder cancer) captured nearly one-third of eligible new patients within a year of launch. Trenfaya is now the #1 IL-23 inhibitor in new-to-brand share for several indications.
• MedTech Headwinds: MedTech underperformed expectations, particularly outside the U.S. Challenges include physician selectivity impacting Abiomed, volume-based procurement in China, and disruptions in the Middle East affecting tender timing.
• Strategic Investments: Completed acquisition of Firefly Bio to enhance oncology pipeline (degraded antibody conjugates) and collaborated with SAIL Biomedicines for in vivo CAR-T therapies. These deals incurred significant non-GAAP charges but are viewed as critical for long-term innovation.
• Orthopedic Separation: Management remains confident in spinning off DePuy Synthes by mid-2027, viewing it as the best option for long-term shareholder value creation.

Innovative Medicine reported worldwide sales of $16.8 billion, an operational increase of 7.9%. This segment contributed approximately 66% to total company revenue. Key growth drivers included Oncology (sales grew ~17%, with strong performance in multiple myeloma and lung cancer products like Darzalex, Peviciti, Tecvali, and Ribravan) and Immunology (Trenfaya grew 68%, while Stelara declined 54% due to biosimilar competition). Neuroscience also performed well, with Kaplaita reaching $1 billion in YTD sales and Spravato growing 36%. MedTech reported worldwide sales of $8.6 billion, an operational increase of 2.5%, contributing approximately 34% to total revenue. Cardiovascular grew 4.1%, driven by Shockwave (+17%) and BodyPulse, though Abiomed declined 1.5%. Surgery declined 1% due to international headwinds, while Orthopedics grew 3.4% and Surgical Vision grew 7.1%.

• Full-Year 2026 Sales Guidance Raised: Operational sales growth is now expected to be 6.7% to 7.1% (midpoint $100.7 billion), up from previous estimates. Reported sales growth is estimated at 7.2% to 7.6% (midpoint $101.2 billion) assuming current FX rates.
• Operating Margin: Expected to decline by approximately 60 basis points, an improvement from the previously cited 75 basis point decline after excluding specific transaction costs.
• Earnings Per Share (EPS): Adjusted operational EPS is guided to $10.95–$11.05 (midpoint $11.00, ~2% growth). Reported adjusted EPS is guided to $11.05–$11.15 (midpoint $11.10, ~2.9% growth). Excluding Firefly/Sail transaction impacts, EPS growth would approach 9%.
• Tax Rate: Effective tax rate guidance tightened to 17.0%–17.5%.
• Net Interest Expense: Lowered to $150 million–$200 million.
• Free Cash Flow: Full-year guidance maintained at approximately $21 billion.
• 2027 Outlook Preview: Management expects 2027 reported sales growth to be similar to 2026 (~5.4% after adjusting for extra week). They anticipate double-digit organic growth by the end of the decade without relying on M&A.

• MedTech International Volatility: Significant disruption in the Middle East has altered ordering patterns and tender timing. Expansion of Volume-Based Procurement (VBP) in China continues to pressure surgery pricing.
• Abiomed Clinical Debate: A study (HRPCI PROTECT-4) raised questions regarding Impella CP efficacy in high-risk PCI, causing temporary headwinds and physician selectivity. Management disputes the study methodology but acknowledges the need for further evidence generation.
• Litigation Costs: The proposed resolution of ovarian talc litigation ($5.5 billion) and other orthopedic separation costs heavily impacted GAAP earnings in Q3.
• Competitive Pressure: Biosimilars continue to erode Stelara’s market share in immunology. Competitive intensity in electrophysiology (PFA) is rising, particularly in Asia Pacific.
• Transaction Integration Risks: Large acquisitions (Firefly Bio, SAIL collaboration) carry integration risks and immediate dilutive impacts on EPS ($0.64 this year, $1.36 next year).

Q: Analyst asked if 'double-digit growth by decade end' relies on internal investments only, and if MedTech urgency implies more M&A or fixing existing portfolio. / A: CFO confirmed double-digit growth assumes internal strategic investments, not M&A. Urgency is focused on fixing current MedTech fundamentals (Cardiovascular, Surgery, Vision) rather than acquiring new areas. Management believes the current portfolio can drive improved performance, citing Otava's future potential in surgery and Abiomed's recovery.